Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Christofferson

Interventional Cardiology Norwalk, OH Medical Doctor

NPI 1427277037 CMS profile 1229640

272 Benedict Ave, Norwalk, OH 44857

Open in the dashboard

General payments

$4,450

158 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Christofferson of Norwalk, OH is reported in the CMS Open Payments database as having received $4,450 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,551 70
2024 General $562 22
2023 General $410 15
2022 General $320 12
2021 General $228 14
2020 General $118 6
2019 General $260 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Christofferson
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ryan Christofferson were reported at $2,551. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ryan Christofferson Interventional Cardiology median Middle half National median
2019 $260 $1,097 $329–$3,048 $163
2020 $118 $473 $161–$1,480 $114
2021 $228 $677 $233–$1,827 $132
2022 $320 $978 $333–$2,724 $149
2023 $410 $1,136 $382–$2,986 $160
2024 $562 $1,181 $395–$3,326 $164
2025 $2,551 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $1,413 27 payments
  2. Medtronic, Inc. $454 8 payments
  3. Abbott Laboratories $327 11 payments
  4. Boston Scientific Corporation $297 6 payments
  5. AstraZeneca Pharmaceuticals LP $266 14 payments
  6. Novartis Pharmaceuticals Corporation $241 13 payments
  7. E.R. Squibb & Sons, L.L.C. $203 13 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $178 9 payments
  9. Janssen Pharmaceuticals, Inc $130 8 payments
  10. Esperion Therapeutics, Inc. $118 6 payments
  11. Other $823 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,999 156 payments
  2. Travel and Lodging $432 1 payment
  3. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $1,331 22 payments
  2. FARXIGA $192 10 payments
  3. LifeVest $178 9 payments
  4. WATCHMAN FLX $169 3 payments
  5. ONYX FRONTIER $165 3 payments
  6. LEQVIO $153 8 payments
  7. ELIQUIS $139 9 payments
  8. XARELTO $130 8 payments
  9. MitraClip $129 1 payment
  10. Abre $128 1 payment
  11. Other $1,850 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,919

Median for Interventional Cardiology: 2,236

Drug cost

$339,510

Median for Interventional Cardiology: $380,412

Branded share of claims

35.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 242 $212,892
Entresto Sacubitril/Valsartan Brand 49 $55,047
Xarelto Rivaroxaban Brand 25 $22,320
Brilinta Ticagrelor Brand 25 $17,961
Praluent Pen Alirocumab Brand 13 $6,232
Dofetilide Generic 35 $5,409
Ranolazine Er Ranolazine Brand 37 $3,983
Metoprolol Succinate Generic 191 $2,324
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 47 $1,861
Atorvastatin Calcium Generic 155 $1,553

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$93,291

Medicare's payments for the services billed

Medicare patients

741

Average age 74

Services billed

1,470

381 women, 360 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 52%
Diabetes 36%
Atrial fibrillation 36%
Chronic kidney disease 35%
Heart failure 29%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $90
$90 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $16
$16 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $16
$16 49 —
DEFINITY
  • Lantheus Medical Imaging, Inc. $15
$15 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $14
$14 242 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record